# A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

> **NCT07090954** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** GR1803 injection
- **DRUG:** Anti-CD38 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT07090954
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2026-07-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090954, "A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07090954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*